194
Participants
Start Date
December 5, 2012
Primary Completion Date
July 4, 2015
Study Completion Date
October 24, 2016
Pimasertib
Subjects will receive pimasertib orally as monotherapy at a dose of 60 milligram (mg) twice daily continuously. Treatment will consist of repeated 21-day cycles which will continue until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first.
Dacarbazine
Subjects will receive dacarbazine intravenously at dose of 1000 milligram per square meter (mg/m\^2) of body surface area every 3 weeks on Day 1 of each 21-days cycle until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first. Eligible subjects with documented tumor progression on dacarbazine will offer to switch to pimasertib treatment.
Research Site, Birmingham
Research Site, Tucson
Research Site, San Francisco
Research Site, Miami Beach
Research Site, Orlando
Research Site, Maywood
Research Site, Indianapolis
Research Site, Boston
Please contact the US Medical Information in, Rockland
Research Site, St Louis
Research Site, Morristown
Research Site, New York
Research Site, Columbus
Research Site, Dallas
Research Site, Madison
Research Site, Adelaide, SA
Research Site, Albury/Wodonga
Research Site, Auchenflower
Research Site, Box Hill
Research Site, Greenslopes
Research Site, Herston
Research Site, Malvern
Research Site, North Sydney
Research Site, Prahran
Research Site, Wendouree
Research Site, Woodville South
Research site, Woolloongabba
Research Site, Brussels
Research Site, Edegem
Research Site, Bordeaux
Research Site, Brest
Research Site, Dijon
Research Site, Lille
Research Site, Lyon
Research Site, Marseille
Research Site, Montpellier
Research Site, Nantes
Research Site, Paris
Research Site, Pierre-Bénite
Research Site, Rennes
Research Site, Toulouse
Research Site, Villejuif
Research Site, Augsburg
Research Site, Berlin
Research Site, Bonn
Research Site, Buxtehude
Research Site, Cologne
Research site, Düsseldorf
Research Site, Erlangen
Research Site, Essen
Research Site, Frankfurt am Main
Research Site, Hamburg
Research Site, Hanover
Research Site, Kiel
Research Site, Leipzig
Research Site, Magdeburg
Research Site, Mainz
Research site, München
Research Site, Münster
Research Site, Plauen
Research Site, Tübingen
Research Site, Würzburg
Research Site, Jerusalem
Research Site, Ramat Gan
Research Site, Tel Aviv
Research Site, Bari
Research Site, Genova
Research Site, Meldola - FC
Research Site, Milan
Research Site, Napoli
Research Site, Padua
Research Site, Roma
Research Site, Siena
Research Site, Groningen
Research Site, Rotterdam
Research Site, Utrecht
Research Site, Christchurch
Research Site, Hamilton
Research Site, Palmerston North
Research Site, Tauranga
Research Site, Durban
Research Site, Johannesburg
Research Site, Pietermaritzburg
Research Site, Pretoria
Research Site, Badalona
Research Site, Barcelona
Research Site, L'Hospitalet de Llobregat
Research Site, Madrid
Research Site, Majadahonda
Research Site, Málaga
Research Site, Pamplona
Research Site, Seville
Research Site, Gothenburg
Research Site, Stockholm
Research Site, Basel
Research Site, Zurich
Research Site, Cambridge
Research Site, London
Research Site, Manchester
Research Site, Newcastle upon Tyne
Research Site, Southampton
Lead Sponsor
Merck KGaA, Darmstadt, Germany
INDUSTRY
EMD Serono
INDUSTRY